NASHVILLE, Tenn., April 26 Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that results from a patient preference study evaluating Kristalose® (lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, will be presented at the 2010 Digestive Disease Week® meeting in New Orleans.
A poster presentation of the study, entitled "An open-label, multi-center, randomized, 7-day crossover study of the preference and safety of powder and liquid lactulose in adult patients with chronic constipation," will be presented on May 4 from 8 a.m. to 5 p.m. Charles F. Barish, M.D., President of Wake Research Associates in Raleigh, N.C. and Clinical Assistant Professor of Medicine at the University of North Carolina School of Medicine, and Bryan Voss, Ph.D., formerly with the Department of Pharmacology at the Vanderbilt University School of Medicine and Research Associate at Cumberland Pharmaceuticals, are the presenting authors.
The data from this trial showed that a majority of study patients with chronic constipation preferred the taste and portability of Kristalose over liquid lactulose. No significant difference in adverse events between patients who took Kristalose and those taking liquid lactulose was noted. Kristalose is the only prescription-strength laxative available in pre-measured powder packets.
Concurrent with the presentation, the poster will be available on Cumberland Pharmaceuticals' website at http://investor.shareholder.com/cpix/events.cfm. Copies may also be obtained by contacting the Company at 615-255-0068.
Digestive Disease Week is the world's largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. It is sponsored by the American Association for the Study of Live Diseases (AASLD), the American Gastroenterology Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society for Surgery of the Alimentary Tract (SSAT). For more information, visit www.ddw.org.
Kristalose® (lactulose) for Oral Solution is a proprietary prescription laxative and the brand name for a unique crystalline form of lactulose that treats acute and chronic constipation. The drug dissolves quickly in four ounces of water, offering patients a virtually tasteless and grit-free alternative to other liquid lactulose treatments. There are no age limitations or length of use restrictions for Kristalose, and it is the only osmotic prescription laxative still sampled to physicians.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning and Kristalose® (lactulose) for Oral Solution, a prescription laxative. The Company also recently launched Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company completed the initial public offering of its common stock in August 2009. For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com.
SOURCE Cumberland Pharmaceuticals Inc.